the National Institutes of Health in the Laboratory of Bioorganic Chemistry in Bethesda, MD, where he He completed his postdoctoral training at MIT and Harvard Med School in the lab of Hidde Ploegh , where he developed new applications of single-domain antibodies (nanobodies). He earned his Ph.D. in Chemistry at the University of Wisconsin-Madison in the lab of Sam Gellman on

He obtained his Ph.D. from the Université de Montréal in 2002 under the guidance of Dr. From 2002-2006 he was a Howard Hughes Post-Doctoral Fellow at the University of Washington in Seattle Moon , where he identified and characterized novel components of the Wnt signaling pathway and a new He is the recipient of the Canada Research Chair in Functional Architecture of Signal Transduction. He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics

He is also an Associate Leader of the Experimental Therapeutics and Metabolism Program and the Director He is a member of the Executive Committee of the Réseau québécois de recherche sur les médicaments. He has received many awards, including a Canada Research Chair, FRSQ scholarships and the CDA/CSEM/Merck He has developed innovative methods for in-cellulo measurement of protein-protein interactions, receptor He has contributed to the generation of many intellectual property agreements and patents, and published

He earned his Ph.D. under Dr. David Tuveson at CSHL where he participated in the development of an organoid system for the culture He explained that he overcame these challenges by reading extensively and contemplating alternative plans However, he decided to undertake another postdoc to gain more experience and confidence. He highlighted the importance of re-evaluating one's work and its potential implications.

From 2013-2018, he was also a Professor at the Skolkovo Institute of Science and Technology (Skoltech Before joining the Department of Cell Biology in 1996 as a postdoc and becoming faculty at Duke in 2000, he He received a Ph.D. in pharmacology in 1992 from the Russian Academy of Medical Sciences and an M.D. Since 2013, he has been elected Chair of the subcommittee for the Dopamine receptors of the International As of August 2022, he has over 270 publications in scientific journals (including Science, Nature, Cell

He continued to work at Warwick as a post-doc studying pro-hormone convertases before securing a 5-year He progressed through the ranks at Warwick to become an Associate Professor before leaving in 2015 to join the Department of Pharmacology at Cambridge, where he is also a Fellow of St John’s College. In 2020, he was promoted to a Readership/Professor in Receptor Pharmacology and was elected a Fellow

In 1989, he returned to Montréal as a professor of biochemistry and a scholar of the Medical Research Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. His work received more than 30,000 citations yielding an h-index of 95. He has supervised the research work of 75 graduate students and 40 post-doctoral fellows. He was also the head of both my Master’s and Ph.D. thesis committees.

He earned his Ph.D. at the Massachusetts Institute of Technology, where he studied MHC class II structure-function His path led him to work in an industry where he assumed various responsibilities and roles in the antibody Aaron has a proven track record as a biologics leader as he led teams to discover and develop novel first-in-class

He introduced molecular pharmacology to a wide range of the company's GPCR projects and was able to initiate He also discovered and championed a novel prostaglandin EP4 drug candidate for development. He finished his career as Head of Bioinformatics for Neuroscience and working on the GSKs novel genetics

In 1989, he returned to Montréal as a professor of biochemistry and a scholar of the Medical Research Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. He is a world-renowned expert in the field of cell signaling and GPCRs and made seminal contributions His work received more than 30,000 citations yielding an h-index of 95. He has supervised the research work of 75 graduate students and 40 post-doctoral fellows.

Authors Chunyang Yi, Jiacheng He, Dan Huang, Yumiao Zhao, Chan Zhang, Xiyun Ye, Ying Huang, Ruth Nussinov

He then moved to the National Institute of Mental Health, researching pharmacological mechanisms of Class As an industry pharmacologist, he consults with numerous pharma and biotechs in understanding and applying He specializes in kinetic analysis of drug action and is known for applying binding kinetics to the development He guided the in vitro biology efforts of the company for numerous drug discovery campaigns.

He continued his graduate studies at the University of Toronto where he earned his MSc (1994) and Ph.D He then moved to Thomas Jefferson University in Philadelphia, PA, for his postdoctoral training in Jeff In 2016 he decided to move his lab to the Medical College of Wisconsin in Milwaukee, WI.

Mid-career, he has worked in finance and developed high-frequency trading systems. He has co-founded consultancy and biotech companies Svarlight and Antiverse. Following this, he joined an early-stage medical device start-up and in 5 years was responsible for project He then returned to information engineering and has been working in machine learning for nearly 10 years

He joined the faculty of Laval University School of Medicine in 1975 and then returned to join Duke’s faculty, where he remained as a James B. He and his laboratory members studied the mechanisms of action and regulation of hormones and neurotransmitters An authoritative and prolific scientist, with over 650 scientific publications, he is most beloved as

He also has globally-recognized expertise in bioluminescence resonance energy transfer (BRET) technology He is Head of Molecular Endocrinology and Pharmacology at the UWA Centre for Medical Research and Harry He currently serves on the Board of the Australasian Society of Clinical and Experimental Pharmacologists Join me and learn more about Kevin’s work and how he manages all his responsibilities. Dr.

At the end of his studies, he was awarded the Pfizer Prize for undergraduate research. He then completed his Ph.D. at Leeds as well as the University’s Ackroyd, Brotherton, and Brown Scholar Following this tremendous experience, he was recruited to be the Principal Investigator of the Receptor At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional At the NIH he was the recipient of the coveted NIH ‘Bench-to-Bedside’ Translational Research Grant Award

At the end of his studies, he was awarded the Pfizer Prize for undergraduate research. He then completed his Ph.D. at Leeds as well as the University’s Ackroyd, Brotherton, and Brown Scholar Following this tremendous experience, he was recruited to be the Principal Investigator of the Receptor At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional At the NIH he was the recipient of the coveted NIH ‘Bench-to-Bedside’ Translational Research Grant Award

At the end of his studies, he was awarded the Pfizer Prize for undergraduate research. He then completed his Ph.D. at Leeds as well as the University’s Ackroyd, Brotherton, and Brown Scholar Following this tremendous experience, he was recruited to be the Principal Investigator of the Receptor At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional At the NIH he was the recipient of the coveted NIH ‘Bench-to-Bedside’ Translational Research Grant Award

at the Pierre and Marie Curie University in Paris and a short internship at Genentech Inc. in South San Francisco, he joined the CNRS as a Research Fellow in 1987 in the INSERM Laboratory directed by Jean-Charles Schwartz in Paris, where he cloned and characterized dopamine D2 and D3 receptor subtypes. From 91 to 94, he was an assistant professor at Duke University in North Carolina, working with Marc Since 2008, he arrived at McGill University with a Canada Research Chair.

He joined the faculty of Laval University School of Medicine in 1975 and then returned to join Duke’s faculty, where he remained as a James B. He and his laboratory members studied the mechanisms of action and regulation of hormones and neurotransmitters An authoritative and prolific scientist, with over 650 scientific publications, he is most beloved as

He participated in various academic competitions, including math, physics, and chemistry contests. John explained that he was drawn to chemistry because it allowed him to build things in his mind and John also mentioned his university application process, which was less stressful than the US system. He then moved to Dan's lab where he met Suzanne and her project. He chose Brian's lab due to his interest in studying conformational changes.

He joined the laboratory of Dr. William Cole at the University of Calgary in 2010 for his Ph.D. where he studied the molecular basis In 2015, He joined Dr. He has been also studying what aspects of GPCR signaling are regulated in a sex-selective manner and He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards

He consults with numerous pharmaceutical, biotech, life science and academic organizations in understanding He regularly teaches courses and publishes chapters and guides on basic and advanced pharmacology and He worked as a pharmacology leader in the pharmaceutical industry for 15 years at Neurocrine Biosciences He completed his Ph.D. in biochemistry, studying allosteric modulation of dopamine receptors, from the He completed postdoctoral training at the National Institute of Mental Health, researching the pharmacological

He joined the faculty of Laval University School of Medicine in 1975 and then returned to join Duke’s faculty, where he remained as a James B. He and his laboratory members studied the mechanisms of action and regulation of hormones and neurotransmitters An authoritative and prolific scientist, with over 650 scientific publications, he is most beloved as

He studied Medicine in Milan and Stockholm, and obtained a PhD in Molecular Medicine and a Clinical Specialisation Between 2009 and 2017, he was a Group Leader at the Institute of Pharmacology and Toxicology and Rudolf He leads a multidisciplinary research team comprising biologists, chemists, physicists, engineers and He has served on multiple panels and committees, including the ENDO Annual Meeting Steering Committee

That summer, he used radioligand binding methods to dissect receptor function from the adenylyl cyclase receptor function in human physiology, receptor molecular pharmacology in cells, and animal models, and as he puts it has now he’s "gone full circle" back to studying GPCRs important in human pathophysiology. Paul Insel on the web Insel Laboratory Institute of Engineering in Medicine UC San Diego UCSD Profiles

He was a postdoc at the University of California in Berkeley, USA. He subsequently returned to Munich as a research associate at the Institute of Pharmaceutical Chemistry Habilitus, he was appointed at the University of Bonn as a Professor of Pharmaceutical Chemistry declining